BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics reported a Q3 2026 net loss of $1.7 million ($0.14 per share), narrowed from $2.1 million a year earlier. The critical figure is liquidity: total cash including restricted cash was only ~$0.35 million at quarter end, far below the quarterly burn rate, and the balance sheet shows a $12.3 million stockholders' deficit and rising payables and employee-related liabilities. Operationally, the company is preparing to launch the Phase 3b ENDURANCE trial of NurOwn in ALS under an FDA-agreed Special Protocol Assessment, and installed former FDA official Peter J. Pitts as Executive Chairman.
Key figures
- Revenue Yoy
- 0
- Net loss q3
- 1733000
- Ga expense q3
- 1092000
- Rd expense q3
- 523000
- Restricted cash
- 185000
- Shares outstanding
- 14259377
- Cash and equivalents
- 163000
- Net loss prior year q3
- 2106000
- Shares outstanding dec 2025
- 11034775
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.